Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 16, 2025 | Mar 28, 2024 | Feb 8, 2023 | Jan 26, 2022 |
| Revenue | $120.8M | $128.9M | $8.57M | – | – |
| Operating expenses | – | – | – | $344.1M | $360.8M |
| Research and development | $37.4M | $151.5M | $224.8M | $272.5M | $282.0M |
| Selling, general and administrative | $26.3M | $39.9M | $50.9M | $71.6M | $78.8M |
| Operating income | $35.9M | -$83.4M | -$276.0M | -$280.5M | -$340.5M |
| Interest expense | $3.79M | $4.62M | $5.29M | – | – |
| Income tax | $31.0K | -$12.0K | $15.0K | $12.0K | $46.0K |
| Net income | $32.7M | -$85.4M | -$276.1M | -$228.3M | -$340.1M |
| EPS, basic | $2.61 | $-11.41 | $-2.61 | $-2.24 | – |
| EPS, diluted | $2.57 | $-11.41 | $-2.61 | $-2.24 | – |
| Weighted shares, basic | 12.5M | 7.49M | 105.9M | 102.0M | – |
| Weighted shares, diluted | 12.7M | 7.49M | 105.9M | 102.0M | – |
| Margins and growth | |||||
| Operating margin | 29.7% | -64.7% | -3219.5% | – | – |
| Net margin | 27.1% | -66.2% | -3220.9% | – | – |
| Revenue growth, year over year | −6.3% | +1,404.0% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 16, 2025 | Mar 28, 2024 | Feb 8, 2023 | Jan 26, 2022 |
| Cash and equivalents | $8.48M | $25.0M | $25.8M | $92.9M | $106.1M |
| Short-term investments | $0 | $17.5M | $25.9M | $149.9M | $265.0M |
| Accounts receivable | $1.25M | $1.48M | $34.1M | $40.2M | $986.0K |
| Inventory | $0 | $10.7M | $9.71M | $1.59M | – |
| Total current assets | $12.2M | $64.9M | $101.9M | $295.1M | $384.6M |
| Property, plant and equipment | $73.0K | $1.29M | $3.86M | $6.30M | $53.8M |
| Total assets | $20.2M | $109.1M | $165.5M | $376.4M | $468.1M |
| Accounts payable | $127.0K | $4.37M | $3.68M | $6.87M | $17.4M |
| Total current liabilities | $14.9M | $134.6M | $142.2M | $78.9M | $105.8M |
| Total liabilities | $58.7M | $206.4M | $264.7M | $249.8M | $188.5M |
| Shareholders' equity | -$38.5M | -$97.3M | -$99.2M | $126.6M | $279.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 16, 2025 | Mar 28, 2024 | Feb 8, 2023 | Jan 26, 2022 |
| Operating cash flow | -$50.9M | -$68.7M | -$193.0M | -$270.4M | -$220.5M |
| Capital expenditures | $0 | $246.0K | $1.22M | $4.19M | $10.6M |
| Free cash flow | -$50.9M | -$69.0M | -$194.2M | -$274.6M | -$231.1M |
| Depreciation and amortization | $2.12M | $5.05M | $4.83M | $5.65M | $9.35M |
| Stock-based compensation | $9.75M | $27.0M | $45.4M | $53.8M | $53.9M |
| Investing cash flow | $18.1M | $8.62M | $123.9M | $203.0M | $22.3M |
| Financing cash flow | $16.1M | $59.3M | $2.01M | $53.1M | $103.9M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 8.1% | 20.9% | 529.4% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 10.2M | +41.3% | SEC |
| Aug 10, 2026 | 10.0M | +42.9% | SEC |
| May 8, 2026 | 9.01M | +51.1% | SEC |
| Mar 10, 2026 | 8.18M | +39.6% | SEC |
| Nov 6, 2025 | 7.21M | +25.2% | SEC |
| Aug 6, 2025 | 7.02M | +42.9% | SEC |
| May 7, 2025 | 5.96M | −95.0% | SEC |
| Feb 26, 2025 | 5.86M | −95.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-25 in Q2 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.